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Background: In the US, serum thyroid-stimulating hormone (TSH) and thyroxine measure-
ments are the fourth- and tenth-commonest laboratory tests ordered, respectively. Diagnosis
of thyroid disorder requires clinical suspicion supported by laboratory values. However, in
the setting of acute illness, both the clinical and laboratory pictures can be confounded.
Objective: To study clinical outcomes and derangement patterns of inpatient thyroid-
function tests.
Design: This retrospective study was conducted at an academic center on admissions
aged ≥18 years and TSH tests performed over a 1-year period. Admissions with active
pregnancy and/or prior thyroid-related diagnosis were excluded.
Main Outcomes: Clinical outcomes were divided based on new diagnosis of thyroid-related
disorder, newly prescribed thyroxine replacement, or antithyroid drugs/ endocrinology referrals,
or both. In order to analyze the derangement patterns of abnormal TSH, only the results of the
first test ordered were considered (as some admissions had multiple TSH tests ordered).
Results: A total of 7,204 admissions aged ≥18 years had TSH tests done. Of these, 1,912
were excluded. Of the 5,292 admissions with no prior thyroid disorder or active pregnancy,
183 (3.46%) were assigned a new diagnosis of thyroid-related disorder, 54 (1.02%) received
treatment/referral, and 46 (0.87%) received both a new diagnosis and treatment/referral.
Based on the TSH results (reference range 0.42–4.0 mIU/L) of the 5,292 admissions, 4,312
(81.5%) and 980 (18.5%) admissions were flagged normal and abnormal, respectively. Of the
980 admissions with one or more abnormal TSH results, 21 (2.14%) had first ordered TSH
<0.05 mIU/L, 855 (87.25%) admissions had first TSH result between 0.05–10 mIU/L, and
lastly 104 (10.61%) were >10 mIU/L.
Conclusion: There is low value in testing inpatients for thyroid disorders, and testing comes
at significant expense to the health-care system.
Keywords: inpatient thyroid-function test, non–thyroidal illness syndrome, sick euthyroid
syndrome, low yield, high-value care
Plain Language Summary
● Serum thyroid-stimulating hormone (TSH) and thyroxine measurements are the fourth-
and tenth-commonest laboratory tests ordered, respectively. In the setting of acute
illness, both the clinical and lab pictures for diagnosing thyroid disorder can be
confounded.
● This retrospective study primarily investigated the number of adult hospitalized admis-
sions that received a new thyroid-related diagnosis and subsequent management based
on thyroid-function tests ordered in the inpatient setting.
● Notably, in the 1-year period of this study, only 46 (0.87%) of the 5,292 admissions
received a new thyroid-related diagnosis resulting in treatment or specialist referral.
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● Additionally, 81.5% of admissions had TSH values within
the reference range. In the 18.5% of admissions with TSH
values outside the reference range, 2.14% had TSH <0.05
mIU/L and 10.6% >10 mIU/L.
Introduction
The 21st century has seen an alarming increase in health-care
costs,1 and one of the major components driving this expen-
diture is unnecessary services.2,3 In the US, Medicare alone
spent a total of $4.29 billion on the top 25 lab tests in 2016.
Among these, thyroid-stimulating hormone (TSH) was the
fourth-commonest lab test, at a cost of $482 million for
21.5 million ordered tests, and thyroxine measurement the
tenth-common, at a cost of $85 million for 7.1 million
ordered tests.4
Clinical features of thyroid dysfunction are non-speci-
fic, and include fatigue, constipation/diarrhea, weight
changes, palpitations, hot/cold intolerance, and brady/
tachycardia. In the normal physiological state, the
hypothalamic–pituitary–thyroid (HPT) axis, via its tightly
controlled feedback mechanism, maintains the level of
serum thyroid hormones within a narrow range.5,6
Intrinsic dysfunction of the HPT axis results in predictable
changes in serum TSH and thyroid hormones.
In patients with critical or non-critical illness, multiple
extrinsic factors (stress, cytokines, interleukins) impact the
HPT axis, resulting in deranged thyroid-function tests
(TFTs), termed non–thyroidal illness syndrome (NTIS) or
sick euthyroid syndrome.7–9 The biochemical disturbances
in NTIS are variable and unpredictable, due to a continuum
of changes the human body goes through during the process
of illness and recovery. Furthermore, certain medications
commonly used in inpatient settings (eg, glucocorticoids,
dopamine agonists, somatostatins) alter TFTs by either
impacting the HPT axis or modulating the secretion or
absorption of thyroid hormones.10 The non-specific clinical
features and biochemical disturbances shared by acute ill-
ness and thyroid disorders make diagnosis of true thyroid
dysfunction challenging, particularly in the inpatient setting.
Subclinical thyroid disease is an increasingly diagnosed
entity nowadays.11 Subclinical disease occurs when TSH is
deranged but thyroid hormones are within normal reference
range, provided thyroid function has been stable for 2–3
months, the HPT axis is normal, and there is an absence of
recent or ongoing severe illness. Based on current evidence,
it is unclear whether treatment is beneficial or harmful in
asymptomatic, nonpregnant adults.12,13
The primary objective of this study was to examine the
clinical outcomes of inpatient TFTs. Secondary objective
included an analysis of the pattern of derangement of the
TFTs - TSH and free T4 (FT4) in those with abnormal TSH
levels.
Methods
After approval by the institutional review board, we con-
ducted a retrospective study at a tertiary-care center on
patients aged ≥18 years who had been admitted to medi-
cine, neurology, and psychiatry services between
October 26, 2017 and October 25, 2018. Exclusion criteria
were active pregnancy and/or prior thyroid-related disor-
ders. Admissions with a history of thyroid-related disorder
were identified when home medications included either
thyroxine-replacement or antithyroid drugs (Appendix 1)
or the admission history mentioned prior thyroid-related
diagnosis (Appendix 2). Next, admissions with no history
of thyroid disorder were divided based on serum-TSH
results, in relation to our lab’s normal reference range
(0.4–4.2 mIU/L), into two groups— normal and abnormal.
For admissions with multiple TSH tests, all values had to
fall within the reference range to qualify for the normal-
TSH group. Even if one test result was outside the refer-
ence range, the admission counted as part of the abnormal-
TSH group. Following this, in both the normal- and abnor-
mal-TSH groups, we searched for admissions that included
either a new diagnosis of thyroid-related disorder based on
ICD10 codes (Appendix 3) or new thyroxine replacement
or antithyroid drugs prescribed at discharge (Appendix 1).
A detailed chart review was performed on all admissions
that met one or both criteria. Final outcomes in both
abnormal- and normal-TSH groups were subgrouped into
four categories: no documented thyroid-related diagnosis
or prescribed treatment with thyroxine-replacement or
antithyroid drugs; documented thyroid-related diagnosis
present, but no treatment or endocrinology referral; pre-
sence of treatment with thyroxine-replacement or antithyr-
oid drugs, but no documented diagnosis; and presence of
both documented thyroid-related diagnosis and treatment
with thyroxine-replacement or antithyroid drugs/endocri-
nology referral present.
In the cohort with abnormal TSH and no prior thyroid-
related disorder or active pregnancy, we studied the pattern of
derangement of TFTs (TSH and FT4). Based on the results of
the first TSH test ordered, admissions in the abnormal-TSH
group were divided into five subgroups: I — <0.05 mIU/L,
II — 0.05–0.39 mIU/L, III — 0.40–4.20 mIU/L, IV —
Dogra et al Dovepress
submit your manuscript | www.dovepress.com
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4.21–10 mIU/L, and V — >10 mIU/L. Subgroup III in the
abnormal-TSH group comprised admissions that had had first
ordered TSH results in the normal reference range (0.40–4.20
mIU/L), but subsequent TSH values outside the reference age
(leading these admissions to qualify for the abnormal-TSH
group). In each subgroup, the first ordered FT4 level was
reviewed and classified as normal and abnormal, based on
our lab’s reference range (0.8–1.7 ng/mL), and each admission
was sorted by presence or absence of a new diagnosis and
treatment or referral.
Results
During the 1-year study period, there were 7,204 admis-
sions and 7,867 TSH tests ordered. A total of 1,912 admis-
sions and 2,127 TSH tests were excluded from the initial
cohort: 1,887 with prior thyroid-related diagnosis and 25
with active pregnancy. As such, the final cohort comprised
5,292 admissions with 5,740 TSH tests. Of note, 422 of
these 5,292 admissions had multiple TSH tests ordered.
The demographic distribution of admissions comprised
2,852 males and 2,440 females (53.89% vs 46.11%),
4,663 Caucasians, 579 African–Americans, 25 Asians,
and 25 other ethnicities, including unknowns (88.11% vs
10.94% vs 0.47% vs 0.47%), with an age range of 18–103
years (mean 55.96±17.4 years). Based on admitting
department, 3,380 (63.87%) admissions were to medicine,
1,290 (24.38%) to neurology, and 622 (11.75%) to
psychiatry.
There were 4,312 admissions with normal-TSH tests
(4,617 TSH tests were obtained in this group; Figure 1).
Of these, 4,260 (98.79%) admissions had 4,561 TSH tests
and 926 FT4 tests, and received neither a diagnosis nor any
treatment. However, 49 (1.14%) admissions had 50 TSH
tests and 12 FT4 tests obtained, and were given a diagnosis
but no treatment or referral was ordered. All of these were
diagnosed with non-toxic thyroid nodules (31 single
nodules, 12 multinodular goiters, six simple goiters).
Finally, three (0.07%) admissions in the normal-TSH
group had six TSH tests and seven FT4 tests, and received
both a diagnosis and treatment/referral. These three diag-
noses comprised two cases of central hypothyroidism and
one case of primary hypothyroidism (Figure 1).
There were 980 admissions with abnormal-TSH tests
(1,123 TSH tests were obtained in this group; Figure 1).
Of these, 841 (85.82%) had 949 TSH tests and 522 FT4
tests, but received neither a diagnosis nor any treatment.
There were 88 (8.98%) admissions with 100 TSH tests and
84 FT4 tests in whom a new diagnosis of thyroid-related
disorder but no treatment or referral was provided. There
were eight (0.82%) admissions with nine TSH tests and
seven FT4 tests that received thyroid-specific treatment,
but with no documented diagnosis provided. Finally,
there were 43 (4.39%) admissions with 65 TSH tests and
54 FT4 tests that received both a diagnosis and treatment
or referral (Figure 1).
For the 131 admissions in the abnormal-TSH group
that had a new thyroid-related diagnosis provided, 49
(37.40%) were diagnosed with hypothyroidism, 12
(9.16%) hyperthyroidism, one (0.76%) autoimmune thyr-
oiditis, 46 (35.11%) subclinical disease, 15 (11.45%) non-
toxic thyroid nodules (single nodule or multinodular/sim-
ple goiter), and eight (6.11%) with sick euthyroid syn-
drome or elevated TSH. Of the 49 admissions with
a new diagnosis of hypothyroidism, treatment or endocri-
nology referral was prescribed to only 26 (53.60%).
Similarly, for 12 admissions with new diagnosis of
hyperthyroidism, only four (33.33%) were prescribed
treatment or endocrinology referral (Figure 1).
Therefore, of the 5,292 admissions with no history of
thyroid diagnosis or pregnancy, 183 (3.46%) received
a new diagnosis of thyroid-related disorder, 54 (1.02%)
treatment or referral, and 46 (0.87%) both a new diagnosis
and treatment or referral. In other words, 5,510 (95.99%)
of the 5,740 TSH tests, 1,448 (89.83%) of the 1,612 FT4
tests, 161 (87.98%) of the 183 total T3 (TT3) tests, and 35
(76.09%) of the 46 free T3 (FT3) tests resulted in no new
diagnosis or treatment/referral (Tables S1 and S2).
We next sought to examine the pattern of derangement of
TFTs (TSH and FT4). The 980 admissions with abnormal
TSH were divided into five subgroups based on the results of
the first ordered TSH. There were 21 admissions (2.14% of
abnormal-TSH group) in subgroup I (TSH <0.05 mIU/L).
Of these, 18 (85.71% of admissions in subgroup I) had FT4
levels measured, with ten results outside the reference range
(or abnormal). In total, five admissions received a new diag-
nosis followed by treatment or referral (Figure 2A).
In subgroup II (TSH 0.05–0.39 mIU/L), there were 255
admissions (26.02% of abnormal-TSH group). Of these,
157 (61.57% of admissions in subgroup II) had FT4 levels
measured, with 18 results outside the reference range. In
this subgroup, there was no new diagnosis followed by
treatment or referral (Figure 2B). In subgroup III, there
were 36 admissions with normal TSH (first ordered value).
Of these, 26 (72.22% of admissions in subgroup III) had
FT4 levels measured, with four showing abnormal.
Dovepress Dogra et al
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Overall, three admissions received both a new diagnosis
and treatment or referral (Figure 2C).
In subgroup IV (TSH 4.21–10 mIU/L), there were 564
admissions (57.55% of abnormal-TSH group). Of these,
313 (55.49% of admissions in subgroup IV) had FT4 levels
measured, with 27 results outside the reference range. In
total, only 13 of these 564 admissions received both a new
diagnosis and treatment/referral (Figure 2D). Lastly, in
subgroup V (TSH >10 mIU/L), there were 104 admissions
(10.61% of abnormal-TSH group). Of these, 85 (81.73%
of admissions in subgroup V) had FT4 levels measured,
with 26 showing abnormal. In total, only 23 of 104 admis-
sions with TSH >10 mIU/L received a new diagnosis and
treatment or referral (Figure 2E).
Discussion
In summary, we found that at a single academic medical
center in the US, over a 1-year period 5,740 TSH tests had
been ordered for 5,292 admissions. TSH tests were abnor-
mal in 980 (18.5%) admissions and led to a new diagnosis
and/or treatment in 139. Notably, a new thyroid diagnosis
and/or treatment was made in 52 admissions with normal
TSH. Of these, 49 were diagnosed with nodular thyroid
disease and two with central hypothyroidism, and TSH
measurement is considered appropriate in these scenarios,
but one was diagnosed with primary hypothyroidism.
This study highlights multiple points. Large proportion
(73.46%) of TSH tests were ordered on admissions with no
known thyroid-related diagnosis. The majority (81.48%) of
the TSH tests yielded results within the normal reference
range. For abnormal TSH, 87.25% were 0.05–10 mIU/L,
followed by 90% of FT4 values within the normal reference
range. An overwhelming proportion (96.39%) received
neither a diagnosis nor treatment. Only a small proportion
of admissions (3.46%) had a new thyroid-related diagnosis,
and an even smaller proportion received treatment/referral
(1.02%). Finally, only 0.87% admissions received both
a diagnosis and treatment/ referral. It is interesting to note
that 26.54% of admissions in our initial cohort had a prior
thyroid-related diagnosis, suggesting that thyroid issues are
important comorbidities in patients requiring hospitalization.
Nonetheless, our results emphasize that inpatient TFTs pro-
vide a low yield of clinical outcomes in patients with no
known thyroid disorder.14–16
Based on recommendations by American Thyroid
Association and American Association of Clinical
Endocrinologists, in hospitalized patients TSH measurement
should be done only if there is an index of suspicion for
thyroid dysfunction.17 Laboratory Medicine Practice
Guidelines suggest use of a widened TSH reference interval
(0.05–10 mIU/L) in hospitalized patients, due to complex
effects of acute or chronic NTIS on TFTs.18 There are
Figure 1 Methodology with results.
Notes: Treatment includes medications and/or endocrinology referrals. a, admissions; t, TSH tests; +, present; –, absent.
Dogra et al Dovepress
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Figure 2 (A) Abnormal TSH subgroup I; (B) abnormal TSH subgroup II; (C) abnormal TSH subgroup III; (D) abnormal TSH subgroup IV; (E) abnormal TSH subgroup V.
Notes: Treatment includes medications and/or endocrinology referrals. FT4, free thyroxine; a, admissions; +, present; –, absent.
Dovepress Dogra et al
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a number of potential explanations for both the number of
tests ordered and the outcomes followed by ordering provi-
ders in the finding of an abnormal TSH. Thyroid disease is
common, and its symptoms can be vague and unspecific.
Excluding thyroid disease is a common step in many diag-
nostic protocols for many different disorders. However, inter-
pretation of TSH results is challenging in the inpatient
setting, as TSH is affected by various medications and clin-
ical scenarios. In many cases, abnormal TSH found in the
inpatient setting is not addressed immediately, but the patient
may be advised to seek repeat lab measurement after dis-
charge and recovery from the illness that led to the admis-
sion. As such, abnormal test results may appear to be ignored
by ordering providers. In other cases, an ordering provider
may be unaware of the potential limitations in interpreting
abnormal-TSH and/or -TFT results (eg, due to NTIS and/or
medication effects), which risks overdiagnosis with unneces-
sary treatment and/or generating unnecessary consultations.
Assessment of thyroid tests obtained in the inpatient setting is
challenging, and likely is an explanation for the outcomes we
observed. However, the limitations mentioned should not
preclude providers from discreetly ordering inpatient thyroid
assays in scenarios with high clinical suspicion of thyroid
dysfunction, including subjects with large goiters or before
initiating chronic treatment with such medications as amio-
darone and lithium.
Overall, 87.25% of total admissions in the abnormal-TSH
group had the first ordered TSH value 0.05–10 mIU/L, fol-
lowed by 90% of first measured FT4 values within the normal
reference range. In this subgroup, there was no new diagnosis
of hyperthyroidism that received treatment or appropriate
endocrinology referral, and three of the eight new diagnoses
of primary hypothyroidism that received treatment had normal
FT4, raising concerns of potential overdiagnosis and unneces-
sary treatment. One strategy to limit unnecessary thyroid
assays in hospitalized patients with no prior thyroid dysfunc-
tion would be to implement reflex testing (automatically gen-
erated FT4 for abnormal TSH results) on a widened TSH
reference interval (0.05–10 mIU/L).19–22 Although this strat-
egy would curtail unneeded FT4 tests, it may not limit ines-
sential TSH tests. Additionally, if used indiscriminately, any
reflex test risks missing cases, such as central hypothyroidism.
Interestingly, in their recent meta-analysis of 58 studies,
Fitzgerald et al demonstrated thyroid-hormone levels (FT4,
TT3/FT3) had a stronger correlation with clinical parameters
than TSH levels, and recommended reconsidering the current
practice of a TSH-based approach to defining thyroid
function.23
Our study has a few limitations: its retrospective design;
the fact that it was a single-center study conducted at an
academic center; the predominantly Caucasian study popula-
tion; inpatient services, such as pediatrics, obstetrics–gynecol-
ogy, and surgery, were not included; we did not research
clinical features linked to the ordering of TFTs; and lastly we
did not analyze providers’ reasoning behind the ordering of the
thyroid assays and arrival at a diagnosis. However, our study
adds to the growing literature demonstrating low yield of
thyroid labs in the inpatient setting.
Conclusion
Inpatient TFTs for diagnosing thyroid disorder have low
overall clinical utility. Lab testing is an indispensable
component of current medical practice; however, efforts
should be made to minimize unnecessary testing and
expenditure.
Ethics and Consent Statement
The study protocol was approved by the institutional
review board of the University of Kentucky, Lexington,
KY, USA. Patient consent to review medical records was
not required by the board, due to the retrospective nature
of the study. Patient data were maintained with confidenti-
ality, in accordance with the ethical standards laid down in
the Declaration of Helsinki.
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All authors of this manuscript declare no conflict of inter-
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